Singh, Rishi KantVerma, Praveen KumarKumar, SandeepShukla, AlokKumar, NaveenKumar, SanjayAcharya, Arbind2025-01-272025-01-2720221452126https://dl.bhu.ac.in/ir/handle/123456789/14282Protein kinase C? (PKC?), belonging to ser/thr protein kinase, perform various biological functions. Overexpression of PKC? has been observed in multiple human malignancies including lymphoma. However, the molecular pathogenesis and involvement of PKC? in Non-Hodgkin lymphoma (NHL) are not clearly understood. Hence, deciphering the role of PKC? in NHL management may provide a better therapeutic option. In the present study, we used selective pharmacological inhibitors G�6976 and Ro320432 that potentially inhibit PKC?-mediated signaling in DL cells, resulting in the inhibition of cell growth and mitochondrial-dependent apoptosis. PKC? inhibition by these inhibitors also displays cell cycle arrest at the G1 phase and causes growth retardation of DL cells. Our results extended the mechanism of PKC? in NHL, and provided potential implications for its therapy. � 2022 Elsevier LtdApoptosisCell cycleDalton's Lymphoma cellsNon-Hodgkin lymphomaProtein kinase C-?Articlehttps://doi.org/10.1016/j.leukres.2021.106772